Meanings of surrogate endpoint in English

Conclusions: CAI is a moderate to good surrogate endpoint for CRBSI.

A PSA-DT of less than 3 months is a surrogate endpoint for PCSM.

It's role as a surrogate endpoint to define risk-adapted strategies is still under evaluation.

To establish efficacy of chemopreventive intervention it is therefore necessary to define surrogate endpoint biomarkers.

These results argue against using changes in serum creatinine as a surrogate endpoint in trials of decongestive strategies.

In conclusion, pCR may be a reliable surrogate endpoint for PST efficacy in a subset of patients undergoing chemotherapy.

It remains, however, to be established whether it can monitor disease progression and serve as surrogate endpoint in clinical trials.

However, WRF has not universally been identified as a poor prognostic sign, challenging the validity of WRF as a surrogate endpoint.

DNA methylation markers may have value as surrogate endpoint biomarkers, but this requires identification of biologically relevant markers suitable for paucicellular, lymphocyte-contaminated clinical samples.

Further work is needed to characterize this behavioral test and to determine whether it may have application as a surrogate endpoint for clinical stroke studies.

First, we discuss the evaluation of surrogate endpoint biomarkers (to shorten a randomized trial) using 2 statistical and 3 biological criteria.

In order to evaluate therapeutic efficacy, surrogate endpoints other than ejection fraction must be found.

These abnormalities could therefore be useful as early markers or surrogate endpoints for studying the microangiopathy.

Methods: CRBSI was used as the gold-standard endpoint, for which colonization, CAI and CLABSI were evaluated as surrogate endpoints.

The assays developed for this project have shown reproducibility and may provide surrogate endpoints to assess vaccination for future trials.

Surrogate endpoint biomarkers are gaining wide acceptance in early diagnosis and short-term cancer chemoprevention trials in place of cancer endpoints.